Yuhan 000100.KS · KRW

Its shares trade on KRX under the ticker 000100.KS. It has been listed since 1 November 1962. In the fiscal year to 31 December 2025, it reported revenue of ₩2.19trn and net income of ₩194.08bn. At that date it held total assets of ₩3.22trn and shareholders' equity of ₩2.31trn.

Yuhan Corp. engages in the manufacture of pharmaceutical, health foods, cosmetics and consumer products. The company is headquartered in Seoul, Seoul. The firm operates its business through three segments. The Pharmaceutical segment is engaged in the production and sale of non-prescription drugs including anti-inflammatory drugs, as well as prescription drugs such as drugs for hepatitis, diabetes, and hypertension. The Life and Health segment is involved in the production and sale of household goods and animal healthcare (AHC) products, including bleach, antibacterial agents. The Overseas Business segment supplies raw drugs to domestic and overseas markets. The firm also sells licenses. The firm distributes its products in domestic and overseas markets such as Europe, Asia and United States.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Wuk Je ChoCo-President, Chief Executive Officer, Director, since 2009₩1.09bn
• Mr. Yeol Hong KimCo-President, Director
• Mr. Byeong Man LeeVice President, Director, since 2015₩620.0m
• Ms. Yeong Mi LeeVice President
• Mr. Yeong Rae LeeVice President, since 2018
• Mr. Se Wung OhVice President
• Ms. Hyo Yeong YimVice President
• Mr. Jae Cheon YooVice President, since 2023
• Mr. Seon Jin GohManaging Director
• Mr. Dae Sik KangManaging Director
• Mr. Jae Hun KimManaging Director
• Mr. Seong Su KimManaging Director, since 2021

Overall

76

Environment

99

Social

99

Governance

31

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.